Compositions and methods for treating allergic inflammation through inhibition of NTRK1
The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods.
1. A method of treating eosinophilic esophagitis (EoE) in a human subject in need thereof, comprising administering to the subject an amount of a tyrosine kinase inhibitor effective to suppress NTRK1 activity in target cells of the human subject, wherein the tyrosine kinase inhibitor is lestaurtinib (CEP-701) or crizotinib.
2. The method of claim 1 , wherein the target cells are epithelial cells.
3. The method of claim 1 , wherein the target cells are cells of a target tissue in the subject.
4. The method of claim 1 , wherein the target tissue is tracheal, lung, or esophageal tissue.
5. The method of claim 1 , wherein the tyrosine kinase inhibitor is effective to suppress NTRK1 activity in the cells of the subject, relative to untreated cells.
6. The method of claim 5 , wherein the tyrosine kinase inhibitor is effective to suppress NTRK1 gene expression or protein expression, or both.
7. The method of claim 1 , wherein the amount of the tyrosine kinase inhibitor is effective to ameliorate one or more symptoms of the EoE.
8. The method of claim 1 , further comprising administering to the subject at least one additional active agent.
9. The method of claim 8 , wherein the at least one additional active agent is an anti-inflammatory agent.
10. The method of claim 8 , wherein the at least one additional active agent is an IL-13 inhibitor, a non-steroidal anti-inflammatory drug (NSAID), a cytokine inhibitor, or a steroid.